The field of the invention relates to compositions and methods for treating and/or preventing immune dysfunction.

The field of the invention relates to compositions and methods for treating and/or preventing immune dysfunction.

Bruton's tyrosine kinase (Btk) inhibitors have the following Formula (I): ##STR00001##

Bruton's tyrosine kinase (Btk) inhibitors have the following Formula (I): ##STR00001##

The present invention relates to certain compounds of Formula (Ia) and pharmaceutically acceptable salts thereof, which exhibit useful pharmacological properties, for example, as agonists of the S1P1 receptor: Also provided by the present invention are pharmaceutical compositions containing compounds of the invention, and methods of using the compounds and compositions of the invention in the treatment of S1P1 receptor-associated disorders, for example, a disease or disorder mediated by lymphocytes, an autoimmune disease or disorder, an inflammatory disease or disorder, an inflammatory skin disease or disorder, cancer, psoriasis, atopic dermatitis, rheumatoid arthritis, Crohn's disease, transplant rejection, multiple sclerosis, systemic lupus erythematosus, ulcerative colitis, type I diabetes, and acne, microbial infections or diseases and viral infections or diseases. ##STR00001##

In one aspect, compounds of Formula AA, or a pharmaceutically acceptable salt thereof, are featured or a pharmaceutically acceptable salt thereof, wherein the variables shown in Formula A can be as defined anywhere herein.

##STR00001##

The present invention relates to a method for freezing and preserving a composition comprising a population of neonatal stromal cells (NSCs) and a cryoprotector, characterised in that it comprises a step of freezing the composition at a temperature of between −70° C. and −140° C., then a step of preserving the composition at between −10° C. and −40° C. The present invention also relates to a composition comprising a population of NSCs and a cryoprotector, characterised in that it is preserved at between −10° C. and −40° C., said NSCs being in particular placental NSCs.

The present disclosure relates to methods for treating Lupus Nephritis (LN) using IL-17 antagonists, e.g., secukinumab. Also disclosed herein are IL-17 antagonists, e.g., IL-17 antibodies, such as secukinumab, for treating LN patients, as well as medicaments, dosing regimens, pharmaceutical formulations, dosage forms, and kits for use in the disclosed uses and methods.

Provided are pharmaceutical compositions comprising a pharmaceutically effective amount of a steroid and a pharmaceutically effective amount of at least one modulator selected from the group consisting of a transient receptor potential (TRP) channel modulator and a proliferatior-activated receptor (PRP) modulator, wherein cannabidiol is not present as the sole modulator, and uses thereof for treating a condition or a symptom thereof, wherein said condition involves inflammation, an immune disease, an autoimmune disease or a combination thereof.

Provided are pharmaceutical compositions comprising a pharmaceutically effective amount of a steroid and a pharmaceutically effective amount of at least one modulator selected from the group consisting of a transient receptor potential (TRP) channel modulator and a proliferatior-activated receptor (PRP) modulator, wherein cannabidiol is not present as the sole modulator, and uses thereof for treating a condition or a symptom thereof, wherein said condition involves inflammation, an immune disease, an autoimmune disease or a combination thereof.